Geoffrey Porges
Stock Analyst at SVB Leerink
(1.35)
# 3,468
Out of 4,944 analysts
122
Total ratings
42.86%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $25.16 | +122.58% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $10.06 | +894.04% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $561.55 | +51.37% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $65.13 | -26.30% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $289.33 | -25.34% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $201.47 | -32.99% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.96 | -7.99% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $120.14 | -37.57% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $48.74 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $12.39 | -19.29% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $9.88 | +7,491.09% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $395.92 | -55.80% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $24.64 | +240.91% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $39.13 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $8.76 | +596.35% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $135.19 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $25.16
Upside: +122.58%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $10.06
Upside: +894.04%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $561.55
Upside: +51.37%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $65.13
Upside: -26.30%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $289.33
Upside: -25.34%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $201.47
Upside: -32.99%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.96
Upside: -7.99%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $120.14
Upside: -37.57%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $48.74
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $12.39
Upside: -19.29%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $9.88
Upside: +7,491.09%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $395.92
Upside: -55.80%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $24.64
Upside: +240.91%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $39.13
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $8.76
Upside: +596.35%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $135.19
Upside: -